Safety and Efficacy of Vyvanse in Adults With Attention-Deficit/Hyperactivity Disorder
Status:
Completed
Trial end date:
2010-07-08
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the maintenance of efficacy, as measured
by Adult ADHD Rating Scale with Prompts (Adult ADHD-RS with prompts) and Clinical Global
Impression - Severity (CGI-S) scores, through a randomized withdrawal design when subjects
with ADHD have been on stable treatment with commercial SPD489 for a minimum of 6 months and
are maintained on their screening dose of commercial SPD489.